If the sector wants signs that the drug pricing debate is having an effect on new launches, look no further than Merck & Co"s (NYSE:MRK) new hepatitis C pill Zepatier. The New Jersey group says it will charge $54,600 for the three-month course of … Read the full article on Seeking Alpha »
Looking For A Hep C Price War? Merck Just Started It - Seeking Alpha
No comments:
Post a Comment